Tramadol Hydrochloride
Product Images NDC 53002-4320

4 FDA label images from Rpk Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 53002-4320). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530024320)

Label Image (Lbl530024320)
Packaging label for Tramadol Hydrochloride 50 mg tablets by RPK Pharmaceuticals, Inc. The label indicates a supply of 20 tablets with directions to take one tablet every 4 to 6 hours as needed or as directed. The label includes patient name and clinic name fields, lot number, expiration date, and various billing NDC codes. The product is designated as Schedule IV (C-IV) and prescription only (Rx only).*
FDA Label Image

7bb9a2e6-figure-01 (Tramadol HCl Tablets Usp 1)

7bb9a2e6-figure-01 (Tramadol HCl Tablets Usp 1)
Chemical structure of Tramadol Hydrochloride showing its specific molecular arrangement, including the methoxyphenyl group, cyclohexanol ring, and dimethylamine side chain, along with the hydrochloride component.*
FDA Label Image

Figure 1 (Tramadol HCl Tablets Usp 2)

Figure 1 (Tramadol HCl Tablets Usp 2)
A pharmacokinetic curve depicting concentration (ng/mL) versus time (hours) for Tramadol and its metabolite M1. The plot compares multiple dose and single dose concentration profiles of Tramadol and M1 over a 48-hour period, showing how their levels change over time.*
FDA Label Image

Fig 2 (Tramadol HCl Tablets Usp 3)

Fig 2 (Tramadol HCl Tablets Usp 3)
Line chart from Protocol CAPSS-047 depicting time to discontinuation due to nausea or vomiting. The x-axis shows days in double-blind treatment (0 to 25), and the y-axis shows percent discontinuing (0 to 50). Two lines compare different dosing schedules: 10 days to 200 mg/day (solid red line) and 16 days to 200 mg/day (blue dashed line).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.